AN
ANVS.US Annovis Bio Inc
- Market cap
- USD 39.8M
- P/E
- -
- P/B
- 25.18x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ANVS.US undervalued?
Graham numberThe Graham number of Annovis Bio Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Annovis Bio Inc fundamental analysis
No fundamental analysis for Annovis Bio Inc yet.
Annovis Bio Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Annovis Bio Inc
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to …
Full company profileAnnovis Bio Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Annovis Bio Inc annual financial statements
| Item | 2012 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 185K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | 174K | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -1.77M | -682K | -714K | -1.61M | -6.64M | -14.5M | -25.5M | -45.0M | -26.7M | -29.7M | - |
| EBITDA | - | -682K | -714K | -378.00 | -5.46M | -14.5M | -25.5M | -56.2M | -22.7M | -28.9M | - |
| Net Income | -8.32M | -682K | -714K | -991K | -5.46M | -14.5M | -25.1M | -56.2M | -24.6M | -28.9M | -12.7B |
| EPS | - | -0.10 | -0.10 | -0.14 | -0.87 | -1.90 | -3.08 | -6.23 | -2.01 | -1.40 | -297 |
| Balance Sheet | |||||||||||
| Total Assets | 2.84M | 358K | 51.0K | 1.12M | 8.12M | 46.0M | 36.0M | 10.2M | 13.9M | 21.1M | 5.50B |
| Total Liabilities | 174K | 7.32M | 7.64M | 9.69M | 578K | 1.51M | 7.70M | 18.0M | 4.62M | 4.23M | 18.7B |
| Shareholders' Equity | 2.66M | -6.97M | -7.59M | -8.58M | 7.54M | 44.5M | 28.3M | -7.75M | 9.31M | 16.9M | -13.2B |
| Cash & Short-term Investments | 72.3K | 347K | 35.3K | 1.86K | 8.07M | 45.7M | 28.4M | 5.75M | 10.6M | 19.5M | 2.82B |
| Total Debt | - | - | - | 500K | - | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.41M | -537K | -559K | -477K | -3.97M | -9.13M | -17.3M | -40.0M | -21.9M | -25.6M | - |
| Capital Expenditure | 79.6K | 0.00 | 0.00 | 0.00 | 3.00 | 0.00 | 4.00 | 4.00 | 4.00 | 0.00 | 0.00 |
| Free Cash Flow | - | -537K | -559K | -477K | -3.97M | -9.13M | -17.3M | -40.0M | -21.9M | -25.6M | - |
| Ratios | |||||||||||
| ROE | -312.9% | - | - | - | -72.4% | -32.6% | -88.8% | - | -264.2% | -171.2% | - |
| ROA | -293.6% | -190.6% | -1,400.0% | -88.7% | -67.3% | -31.5% | -69.8% | -550.6% | -176.6% | -136.9% | -230.0% |
| Net Profit Margin | -4,495.6% | - | - | - | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Annovis Bio Inc dividends
Annovis Bio Inc has not paid dividends in the last 9 fiscal years.
Who owns Annovis Bio Inc
- Insiders 16.17%
- Institutions 15.16%
- Public & others 68.67%
- Shares outstanding 43.0M
- Free float 35.9M
Top funds holding ANVS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.22M | 4.48% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 152K | 0.56% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 93.8K | 0.34% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 45.7K | 0.17% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 42.0K | 0.15% | 0.00% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 32.7K | 0.12% | 0.00% | Oct 2026 |
| Vanguard Balanced Index Inv | 21.0K | 0.08% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 11.2K | 0.04% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 6.99K | 0.03% | 0.00% | Sep 2026 |
| JHVIT Total Stock Market Index I | 959.00 | 0.00% | +72.17% | Aug 2026 |
Top institutions holding ANVS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Empery Asset Management, LP | 2.40M | 5.63% | 0.00% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 1.84M | 4.32% | +55.14% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.65M | 3.86% | +88.83% | Jun 2026 |
| Tudor Investment Corp Et AL | 1.36M | 3.18% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 1.00M | 2.35% | +188.32% | Jun 2026 |
| Two Sigma Investments LLC | 580K | 1.36% | -7.66% | Jun 2026 |
| Geode Capital Management, LLC | 284K | 0.67% | +14.67% | Jun 2026 |
| BlackRock Inc | 250K | 0.59% | +79.07% | Jun 2026 |
| Citadel Advisors Llc | 244K | 0.57% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 178K | 0.42% | +34.45% | Jun 2026 |
| Susquehanna International Group, LLP | 147K | 0.34% | -32.76% | Jun 2026 |
| Quadrature Capital Limited | 90.9K | 0.21% | 0.00% | Jun 2026 |
| State Street Corp | 77.7K | 0.18% | 0.00% | Jun 2026 |
| Northern Trust Corp | 68.1K | 0.16% | -51.97% | Jun 2026 |
| First National Trust Co | 60.0K | 0.14% | +50.00% | Jun 2026 |
| Sherry Group Inc | 57.3K | 0.13% | 0.00% | Sep 2026 |
| GSA Capital Partners LLP | 49.9K | 0.12% | +9.87% | Jun 2026 |
| Greenwich Wealth Management LLC | 48.4K | 0.11% | +2.98% | Jun 2026 |
| Headlands Technologies LLC | 48.1K | 0.11% | 0.00% | Jun 2026 |
| Wescott Financial Advisory Group, LLC | 41.6K | 0.10% | 0.00% | Jun 2026 |
Annovis Bio Inc company profile
- Company name
- Annovis Bio Inc
- Ticker
- ANVS.US
- Exchange
- USA Stocks
- Listed since
- Feb 12, 2010
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
- Fiscal year end
- December
- Address
- 101 Lindenwood Drive, Malvern, PA, United States, 19355
- Phone
- 484 875 3192
- Website
- annovisbio.com
About Annovis Bio Inc
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Annovis Bio Inc management
5- Dr. Maria L. Maccecchini Ph.D.Founder, Acting CFO, CEO, President & Executive Director · born 1951
- Dr. Cheng Fang Ph.D.Chief Scientific Officer
- Ms. Eve M. Damiano M.S., RACSenior Vice President of Regulatory Operations
- Mr. Blake Jensen M.B.A.Head of Quality
- Ms. Hilda MaibachSenior Vice President of Statistics